Kornimate/medical-research-clean huggingface dataset:
wound dressings for hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: the primary purpose of this research is to determine how the types of wound dressings affect quality of life for people with hidradenitis suppurativa (hs).


Eligibility criteria:
inclusion criteria: * men and women ≥18 years of age * diagnosed with hidradenitis suppurativa (all stages of disease) by dermatologist * presence of at least one lesion with active drainage * willing and able to provide informed consent exclusion criteria: * subjects younger than 18-years-old. * prisoners * pregnant or lactating women * adults unable to consent
a prospective, open, non-controlled clinical investigation to evaluate the performance and safety of an antimicrobial foam transferring dressing in patients with malignant wounds

Conditions: Malignant Wounds

Summary: this is a prospective, open, non-controlled clinical investigation to evaluate the performance and safety of using mepilex transfer ag on a malignant wound. approximately ten to fifteen (10-15) subjects from one to three centers in europe, presenting with a malignant (fungating) wound will be enrolled into the study. eligible subjects will have one malignant (fungating) wound selected as a "study site". subjects will be followed for a one-week observation period with their existing product followed by a 4-week investigation period using mepilex transfer ag.


Eligibility criteria:
inclusion criteria: * presence of at least one exuding malignant (fungating) wound in need for antimicrobial treatment * both genders with an age ≥ 18 years at randomization * subjects with a suspected survival time of \> 3 months * signed informed consent exclusion criteria: * any known or suspected systemic infection * use of metronidazole is not allowed during the investigation period * any known sensitivity to silver or other components/products used in this study. * major uncontrolled systemic disorders such as hepatic, renal, neurologic, or endocrinologic disorders. * participation in another investigational study while participating in this study.

Keywords: presence of at least one exuding malignant (fungating) wound in need for antimicrobial treatment
sardine-enriched diet for prevention type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; PreDiabetes; Diet Habit; Diabetes; Nutritional and Metabolic Disease

Summary: the hypothesis formulated is that 200 g of sardine on a weekly basis will have a favourable impact avoiding the natural development of the pathology due to changes in the biochemical profile, the anthropometrics, inflammatory markers, changes in gut microbiota populations, also in transcriptomics and metabolomics.


Eligibility criteria:
inclusion criteria: * glycaemia between 100-125 md / dl or ≥5.7% hba1c exclusion criteria: * treatment with oral antidiabetic drugs * any nutritional education to prevent t2d * suspect or known hypersensitivity to sardine or related fish * chronic treatment with oral steroids and / or aines * treatment with oral antidiabetic agents and / or insulin * treatment with immunosuppressive drugs * diagnosis of active neoplasm * diagnosis of hiv or aids * abnormal liver profile (\> 6 times normal values) * diagnosis of acute psychiatric sdr * presence of serious acute concomitant disease, which it requires more than 7 days of recovery. * major cardiovascular event (stroke, myocardial infarction) in the month prior to randomization. * any other condition that the investigator considers to be inoperative so that the subject conducts the study.

Keywords: diabetes t2d diet nutrition prediabetes sardine elderly
effect of case-management using home monitoring on diabetes and blood pressure outcomes

Conditions: Diabetes Mellitus

Summary: this is a randomized trial designed to determine if adoption of the chronic care model in conjunction with nurse case management, home telemonitoring, and home hba1c monitoring can improve glycemic control compared to patients receiving usual case management. we hypothesize that nurse case management, with home telemonitoring of blood sugars and home hba1c measurement will result in additional improvements in glycemic control compared to isolated nurse case management. specifically, the telemonitoring group will have an hba1c 0.5% lower compared to usual nurse case management. secondary aims include an additional 5 mmhg improvement in systolic blood pressure (among patients with hypertension at the time of enrollment), improved patient satisfaction with treatment, improved medication adherence, reduced incidence of hypoglycemia, and reduced case manager time in the telemonitoring/home hba1c group compared with usual caes management. the study will enroll 460 diabetic patients with hba1c values greater than 8.5%, age 75 years or younger, who have a active land-line for telephone communication. patients will be enrolled and actively case managed for 9 months.


Eligibility criteria:
inclusion criteria: * enrolled at minneapolis vamc, * type 1 or 2 diabetes, * hba1c \>8.5%, * active land-line telephone connection exclusion criteria: * age \>75 years, * primary care provider unwilling to have patient enrolled, * active dialysis, * resident of assisted living facility, * research participant in previous diabetes case management study, * life expectancy \<1 year, * severe mental health condition, * active substance abuse, * pregnant or planning on becoming pregnant

Keywords: diabetes mellitus chronic care case management telemedicine
heart failure and peritoneal ultrafiltration

Conditions: Congestive Heart Failure

Summary: the objective of the study is to determine if the addition of peritoneal ultrafiltration to standard therapy in treatment-resistant severe heart failure patients will improve fluid balance and functional capacity such that they will spend less time in the hospital and have an improved ambulatory quality of life in comparison to patients who remain on standard therapy alone.


Eligibility criteria:
inclusion criteria: * adults with congestive heart failure (chf) who remain fluid overloaded despite standard treatment. exclusion criteria: * patients who have reversible chf or have diseases or conditions that would contraindicate the use of peritoneal dialysis.
neonatal hypotonia associated with in utero exposure to antidepressant

Conditions: Neonatal Hypotonia; Antidepressant Drug Adverse Reaction; Pregnancy Related

Summary: to better characterize the neonatal hypotonia associated with in utero exposure to antidepressants, so far limited to clinical cases, we will perform an observational retrospective pharmacovigilance study, using two databases. first, disproportionality analysis in vigibase®, the world health organization global database, will be perform between antidepressant drugs and neonatal hypotonia . second, narratives from the french national pharmacovigilance database will be extracted.


Eligibility criteria:
inclusion criteria: * neonatal hypotonia newborns cases associated with in utero exposure to antidepressant drugs exclusion criteria: * reports with maternal suicide, congenital malformation and hypotonia occurring only during breastfeeding
effects of jones technique and cross friction massage on cervicogenic headache.

Conditions: Cervicogenic Headache

Summary: cervicogenic headache is a very incessant issue that is often faced by the general population. cervicogenic headache is a significant issue in patients with upper cervical dysfunction. however, its physical therapy management is a subject of debate. as the comparative effects of jones technique and cross-friction massage have never been investigated in patients with cervicogenic headache and neck pain, this study aims to investigate the effects of these treatments on two study groups (group a\&b) respectively.

this study will be a randomized clinical trial and will be conducted in al-khidmat foundation sahiwal. the study will be completed within the time duration of six months. a nonprobability convenience sampling technique will be used to collect the data. the sample size of 30 patients will be taken in this study, aged 20-to 50 years, will be allocated to two groups, group a (jones technique) and group b (cross friction massage). strain counter strain technique also known as the jones technique will be performed with the patient laid supine on the treatment table, taking them to a position of comfort by extending, side-bending, and rotating the head away (esara) from the tp until the tp pain has reduced. continues to monitor, maintaining the patient's position for 90 seconds. after 90 seconds have elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks. group b will get cross friction massage for 15-20 minutes. participants will be treated 3 times per week for 6 weeks. pre and post-treatment readings will be taken in 1st session and 6th week respectively. assessment will be done via a 6-item headache impact scale and neck disability index. the neck disability index will be used to examine neck pain intensity and cervicogenic headache symptoms. the 6-item headache impact test scale will be used to examine headache severity and its adverse effects on social life and functions. a goniometer will be used to assess the rotation range of motion.

Eligibility criteria:
inclusion criteria: * headache with neck stiffness and/or pain. * headache for the past 3 months at least once per week * aged 20-40 years * chronic neck pain for more than 3 months * baseline ndi score of at least 20% (10 points). * forward head posture exclusion criteria * headache with neck stiffness and/or pain. * headache for the past 3 months at least once per week * aged 20-40 years * chronic neck pain for more than 3 months * baseline ndi score of at least 20% (10 points). * forward head posture

Keywords: strain counter strain, cervicogenic headache neck pain cross friction massage,
negative pressure vs. compression in venous ulcers

Conditions: Varicose Ulcer

Summary: this study randomises patients with venous leg ulcers, to be managed either using conventional compression bandages or a bridged vacuum assisted closure system under compression.

venous ulcers are characterised by a cyclical pattern of healing and recurrence, with recurrence rates between 45 and 70% at one year. venous leg ulceration has been identified as a common source of morbidity and reduced quality of life, especially in the elderly population. non-healing ulcers place the patient at a much higher risk for lower extremity amputation. compression therapy is currently recognised as the main treatment for venous leg ulcers. external compression is applied as a therapy for venous leg ulcers, in an attempt to reverse the increased hydrostatic pressure in the veins. the application of negative pressure to successfully treat and aid in the healing of open wounds has been studied extensively for decades, demonstrating favourable clinical results. however, there is a lack of evidence in the literature regarding the use of vac in venous ulcers. the combination of negative pressure therapy and compression therapy is theorized to provide the benefits of both individual therapies. as such, the utilization of the bridge vac under a compression dressing is expected to expedite the healing of venous ulcers. the investigators aim to randomise patients with venous ulcers to either be managed using conventional compression dressings or combined bridge vacuum assisted closure with compression dressings.

Eligibility criteria:
inclusion criteria: * aged 18 years or more * provide written informed consent * venous ulcer present, greater than 10cm2 in surface area * a c6 grading in the ceap classification exclusion criteria: pregnant (confirmed by β-hcg analysis). female patients of childbearing potential are advised to adhere to an appropriate form of contraception, and those unwilling to follow contraceptive advice are excluded from the study * involvement in another clinical trial in the previous six months * legal incapacity * patient is bed-ridden or immobile * ulcer smaller than 10cm2 in surface area * ischaemic ulcer/s present * diabetic ulcer/s present * malignant ulceration/s present * ulcer exposing bone or tendon * osteomyelitis * pseudomonas infection * presence of gangrene * deep venous thrombosis (dvt) present * connective tissue disease present * presence of any illness that could limit long-term compliance (e.g. epilepsy)

Keywords: varicose ulcer compression therapy negative pressure vacuum assisted closure
does increase in appetite after iron treatment induced by ghrelin hormone

Conditions: Anemia

Summary: the purpose of this study is to examine whether iron therapy in patients with intravenous iron deficiency anemia causes an increase in appetite. and whether this increase is mediated by the hormone ghrelin.

prior to iron treatment investigator will sample subject blood for: counting blood, iron sector indices, renal function, electrolytes, and measure the level of ghrelin fasting plasma. in addition, the patient will fill a structured questionnaire that examines appetite levels. participants will be asked to answer a structured questionnaire which will include information on demographics, clinical data (fever, allergies, weight, height) and comorbidities. additional data on laboratory tests, comorbidities, medication and regular blood and urine cultures results will be taken from the medical file. iron treatment will be given according to local standard procedure . at the end of the treatment ghrelin levels and questionaire will be retaken . iron deficiency anemia is defined: hemoglobin \<12 gr / dl in women and hb \<13 gr / dl in men with ferritin \<15 ng / ml.

Eligibility criteria:
inclusion criteria: * iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects * sign and dated informed consent form. exclusion criteria: * chronic inflammatory disease. * chronic renal failure * active cancer. * active infectious disease. * non iron deficiency anemia. * pregnancy.
the ampk modulator metformin as a novel adjunct to conventional therapy in patients with knee osteoarthritis

Conditions: Osteo Arthritis Knee

Summary: metformin alleviates drug-induced osteoarthritis (oa)-like change in mice knee joint through activating autophagy and downregulating apoptosis. metformin exerts its protective effects against oa through the ampka2/ sirt1 pathway. metformin suppresses il-1β-induced oxidative and osteoarthritis-like inflammatory changes by enhancing the sirt3/pink1/parkin signaling pathway, thereby indicating metformin's potential in prevention and treatment of osteoarthritic joint disease.


Eligibility criteria:
inclusion criteria: * primary osteoarthritis patients recruited were between 30 to 60 years of age, with x-ray confirmed kellgren-lawrence grade13 ii or iii severity primary tibiofemoral oa, according to the american college of rheumatology criteria. exclusion criteria: those patients were excluded from the present study who: * were of age less than 30 years or more than 60 years * presented with active concomitant gastroduodenal disorders, hepatic and renal impairment within last 30 days prior to receiving the study drug * were diagnosed to have any inflammatory arthritis, gout or acute trauma of the knee, hip or spine; accompanying oa of the hip of sufficient severity to interfere with the functional assessment of the knee * had previous or ongoing treatment with oral sysdoa (e.g., glucosamine sulphate, chondroitin sulphate, diacerein, piascledine), anti-depressants, tranquillisers, antacids or antibiotics; were having active cardiac lesion or hypertension, were pregnant females and those who were planning their pregnancy during the study * were having a known hypersensitivity to the used medications * have persistent diarrhoea or laxative use; severe gastrointestinal disorders, severe obesity, severe parenchymal organ disease, or anaemia (haemoglobin\< 10.0 g/ dl or haematocrit \< 30%). * patients who received oral, intramuscular, intraarticular or soft tissue injections of corticosteroids within last eight weeks before receiving the first dose of the study medication, or had undergone joint lavage and arthroscopic procedures in the previous 6 months, were also excluded.
intravascular ultrasound in patients with end-stage renal disease on dialysis

Conditions: End Stage Renal Disease

Summary: hemodialysis represents a life line of patients with end stage renal disease, who are commonly maintained on hemodialysis through catheters. prolonged exposure to these catheters eventually damages the walls of veins, which results in stenosis at the local site. this condition is called central venous stenosis (cvs) and affects number of patients on hemodialysis in the united states and can compromise the dialysis efficacy. the current diagnostic modality for cvs is venography, which has several limitations. this study proposes to examine intravenous ultrasound (ivus) as a potentially superior modality, which will provide additional information.


Eligibility criteria:
inclusion criteria: * esrd (end stage renal disease) patients at bmc (boston medical center) * receiving hemodialysis * has a dialysis access malfunction * undergoing a diagnostic fistulogram for the dialysis access malfunction exclusion criteria: * none

Keywords: intravenous ultrasound (ivus) central venous stenosis (cvs) hemodialysis dialysis access malfunction fistulogram stenosis virtual histology (vh-ivus) software
preparing spanish-speaking older adults for advance care planning and medical decision making (prepare)

Conditions: Chronic Disease

Summary: in partnership with patients, caregivers, advocacy groups and clinicians, the investigators plan to: aim 1: adapt and refine prepare in spanish through cognitive interviews with spanish-speaking latinos and stakeholders. aim 2: conduct a randomized clinical trial (rct) to compare the efficacy of prepare plus a previously-tested, easy-to-read- ad (intervention) versus the ad alone (control) to: 2a. engage older spanish-speaking latinos in multiple acp behaviors (i.e., identify and discuss wishes with surrogates and clinicians and complete ads) measured by self-report, chart review, surrogate reports, and 2b. direct observation. 2c. improve self-efficacy and satisfaction with medical decision making. 2d. determine whether prepare efficacy varies by literacy, decision control preferences, and clinician-patient language concordance. aim 3: disseminate prepare with input from patients, surrogates, and stakeholders.

prepare is a website (www.prepareforyourcare.org) that teaches patients how to identify what is most important in life, how to communicate their preferences to clinicians and loved ones, and how to make informed decisions. it is written at a 5th grade level and includes voice-overs of text and closed captioning of videos that model advance care planning behaviors. the goal of this proposal is to test the efficacy of prepare plus an easy-to-read advance directive, versus an advance directive alone, to improve patient engagement in multiple advance care planning behaviors including discussions with surrogate decision makers and clinicians in addition to advance directive completion. the investigators will also determine whether prepare can empower and activate patients within clinical encounters with their clinicians and help to decrease health disparities in advance care planning.

Eligibility criteria:
inclusion criteria: * spanish-speaking adults ≥ 55 years of age * ≥ 2 chronic illnesses determined by icd-9 codes * ≥ 2 visits with an outpatient primary care clinician at san francisco general hospital in the past year * ≥ 2 additional outpatient/inpatient visits to san francisco general hospital in the past year exclusion criteria: * deaf, blind, demented or psychotic as determined by icd-9 codes * too mentally or physically ill to participate as determined by their clinicians * moderate or severe cognitive impairment as determined by the short portable mental status questionnaire (spmsq), and mild cognitive impairment by the spmsq plus an abnormal mini-cog (scores minimally affected by education/ethnicity) * self-reported poor vision and inability to see the words on a newspaper * lack of a telephone (for follow-up) * traveling or moving out of the area for ≥3 months during the study follow-up period.

Keywords: advance care planning latino health medical decision making health literacy limited english proficiency aging
amg 386 drug-drug interaction study with paclitaxel

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with amg 386 to determine whether amg 386 alters the pharmacokinetics of paclitaxel

eligible subjects enrolled in the study will begin receiving paclitaxel on a three weeks on / one week off schedule at study day 1 and weekly amg 386 beginning at study day 8. the pharmacokinetic portion of the study occurs during the first two study cycles with intensive pk collections on study weeks 1, 6 and 8. once the pharmacokinetic assessment period is completed, continued combination therapy with amg 386 and paclitaxel or single-agent amg 386 will be administered at the investigator's discretion until progression, unacceptable toxicity develops, or study withdrawal.

Eligibility criteria:
inclusion criteria: * men or women ≥ 18 years of age * have a pathologically documented, and definitely diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available * eastern cooperative oncology group (ecog) performance status ≤ 2 * normal or clinically acceptable ecg (12 lead reporting pr, qrs, qtc) exclusion criteria: * subjects with gastric cancer or any malignancy with purely squamous cell histology * known history of primary central nervous system (cns) tumors or cns metastases * myocardial infarction within 1 year before study day 1, unstable or uncontrolled disease/condition related to or affecting cardiac function * history of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study day 1 * a baseline ecg qtc interval \> 450 msec * active grade 2 or greater peripheral vascular disease * history of pulmonary hemorrhage or gross hemoptysis within 6 months before study day 1 * non-healing wound, ulcer (including gastrointestinal) or fracture * known positive test for human immunodeficiency virus infection, or active hepatitis b or hepatitis c infection * major surgery within 1 month before study day 1 * concurrent antitumor treatment within 4 weeks (6 weeks for nitrosoureas or mitomycin) before study day 1 * unable to tolerate iv administration or repeated blood withdrawal * hypersensitivity to paclitaxel or drugs using the vehicle cremophor * known sensitivity to mammalian-derived products, bacterially-produced proteins, or any of the products to be administered during dosing * chronic neuropathy grade ≥ 1 * concurrent or prior treatment with 2c8 and 3a4 substrates * enrolled in or has not yet completed at least 30 days (prior to study day 1) since ending other investigational device or drug, or currently receiving other investigational treatment. * men and woman of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and an additional 6 months after the last dose of amg 386 * women who are lactating/breastfeeding * women with a positive pregnancy test * women planning to become pregnant during the duration of the study

Keywords: sarcomas carcinomas